Subcellular fate and off-target effects of siRNA, shRNA, and miRNA

Saurabh Singh, Ajit S. Narang, Ram I. Mahato

Research output: Contribution to journalReview article

108 Citations (Scopus)

Abstract

RNA interference (RNAi) strategies include double-stranded RNA (dsRNA), small interfering RNA (siRNA), short hairpin RNA (shRNA), and microRNA (miRNA). As this is a highly specific technique, efforts have been made to utilize RNAi towards potential knock down of disease-causing genes in a targeted fashion. RNAi has the potential to selectively inhibit gene expression by degrading or blocking the translation of the target mRNA. However, delivering these RNAs to specific cells presents a significant challenge. Some of these challenges result from the necessity of traversing the circulatory system while avoiding kidney filtration, degradation by endonucleases, aggregation with serum proteins, and uptake by phagocytes. Further, non-specific delivery may result in side-effects, including the activation of immune response. We discuss the challenges in the systemic delivery to target cells, cellular uptake, endosomal release and intracellular transport of RNAi drugs and recent progress in overcoming these barriers. We also discuss approaches that increase the specificity and metabolic stability and reduce the off-target effects of RNAi strategy.

Original languageEnglish (US)
Pages (from-to)2996-3015
Number of pages20
JournalPharmaceutical Research
Volume28
Issue number12
DOIs
StatePublished - Dec 1 2011

Fingerprint

RNA Interference
MicroRNAs
Small Interfering RNA
RNA
Double-Stranded RNA
Endonucleases
Protein Biosynthesis
Phagocytes
Cardiovascular System
Blood Proteins
Gene expression
Kidney
Gene Expression
Agglomeration
Genes
Chemical activation
Degradation
Messenger RNA
Pharmaceutical Preparations

Keywords

  • RNA interference
  • cellular uptake
  • intracellular trafficking
  • miRNA
  • shRNA
  • siRNA

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry
  • Pharmacology (medical)

Cite this

Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. / Singh, Saurabh; Narang, Ajit S.; Mahato, Ram I.

In: Pharmaceutical Research, Vol. 28, No. 12, 01.12.2011, p. 2996-3015.

Research output: Contribution to journalReview article

Singh, Saurabh ; Narang, Ajit S. ; Mahato, Ram I. / Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. In: Pharmaceutical Research. 2011 ; Vol. 28, No. 12. pp. 2996-3015.
@article{78c8666ac4a049dbbed455f33f2a42ba,
title = "Subcellular fate and off-target effects of siRNA, shRNA, and miRNA",
abstract = "RNA interference (RNAi) strategies include double-stranded RNA (dsRNA), small interfering RNA (siRNA), short hairpin RNA (shRNA), and microRNA (miRNA). As this is a highly specific technique, efforts have been made to utilize RNAi towards potential knock down of disease-causing genes in a targeted fashion. RNAi has the potential to selectively inhibit gene expression by degrading or blocking the translation of the target mRNA. However, delivering these RNAs to specific cells presents a significant challenge. Some of these challenges result from the necessity of traversing the circulatory system while avoiding kidney filtration, degradation by endonucleases, aggregation with serum proteins, and uptake by phagocytes. Further, non-specific delivery may result in side-effects, including the activation of immune response. We discuss the challenges in the systemic delivery to target cells, cellular uptake, endosomal release and intracellular transport of RNAi drugs and recent progress in overcoming these barriers. We also discuss approaches that increase the specificity and metabolic stability and reduce the off-target effects of RNAi strategy.",
keywords = "RNA interference, cellular uptake, intracellular trafficking, miRNA, shRNA, siRNA",
author = "Saurabh Singh and Narang, {Ajit S.} and Mahato, {Ram I.}",
year = "2011",
month = "12",
day = "1",
doi = "10.1007/s11095-011-0608-1",
language = "English (US)",
volume = "28",
pages = "2996--3015",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Subcellular fate and off-target effects of siRNA, shRNA, and miRNA

AU - Singh, Saurabh

AU - Narang, Ajit S.

AU - Mahato, Ram I.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - RNA interference (RNAi) strategies include double-stranded RNA (dsRNA), small interfering RNA (siRNA), short hairpin RNA (shRNA), and microRNA (miRNA). As this is a highly specific technique, efforts have been made to utilize RNAi towards potential knock down of disease-causing genes in a targeted fashion. RNAi has the potential to selectively inhibit gene expression by degrading or blocking the translation of the target mRNA. However, delivering these RNAs to specific cells presents a significant challenge. Some of these challenges result from the necessity of traversing the circulatory system while avoiding kidney filtration, degradation by endonucleases, aggregation with serum proteins, and uptake by phagocytes. Further, non-specific delivery may result in side-effects, including the activation of immune response. We discuss the challenges in the systemic delivery to target cells, cellular uptake, endosomal release and intracellular transport of RNAi drugs and recent progress in overcoming these barriers. We also discuss approaches that increase the specificity and metabolic stability and reduce the off-target effects of RNAi strategy.

AB - RNA interference (RNAi) strategies include double-stranded RNA (dsRNA), small interfering RNA (siRNA), short hairpin RNA (shRNA), and microRNA (miRNA). As this is a highly specific technique, efforts have been made to utilize RNAi towards potential knock down of disease-causing genes in a targeted fashion. RNAi has the potential to selectively inhibit gene expression by degrading or blocking the translation of the target mRNA. However, delivering these RNAs to specific cells presents a significant challenge. Some of these challenges result from the necessity of traversing the circulatory system while avoiding kidney filtration, degradation by endonucleases, aggregation with serum proteins, and uptake by phagocytes. Further, non-specific delivery may result in side-effects, including the activation of immune response. We discuss the challenges in the systemic delivery to target cells, cellular uptake, endosomal release and intracellular transport of RNAi drugs and recent progress in overcoming these barriers. We also discuss approaches that increase the specificity and metabolic stability and reduce the off-target effects of RNAi strategy.

KW - RNA interference

KW - cellular uptake

KW - intracellular trafficking

KW - miRNA

KW - shRNA

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=83555166124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83555166124&partnerID=8YFLogxK

U2 - 10.1007/s11095-011-0608-1

DO - 10.1007/s11095-011-0608-1

M3 - Review article

C2 - 22033880

AN - SCOPUS:83555166124

VL - 28

SP - 2996

EP - 3015

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 12

ER -